AstraZeneca Q3 Adjusted Earnings, Revenue Rise; Reaffirms 2026 Outlook

04:08 AM EDT, 10/30/2026 (MT Newswires) -- AstraZeneca (AZN) reported fiscal Q3 core net income Friday of $2.79 per diluted share, up 17% from a year earlier. Analysts polled by FactSet expected $2.60. Revenue for the quarter ended Sept. 30 was $16.21 billion, up from $15.19 billion a year earlier. Analysts expected $16.02 billion. The company reaffirmed its 2026 outlook for core EPS and revenue to grow by low double-digit and mid-to-high single-digit percentages, respectively. Analysts surveyed by FactSet expect EPS of $10.24 on revenue of $62.87 billion. Shares were 3% higher in premarket trade.